Radiomics in Pancreatic Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-01-31

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The images of patients with pancreatic cancer were collected and analyzed based on the methodes of radiomics

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients with pancreatic cancer

Patients with pancreatic tumors diagnosed clinically or pathologically

No interventions assigned to this group

Participants without pancreatic cancer

Participants who judged the pancreas to be completely healthy through medical examination

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Gender unlimited, 18-80 years old;
* Received abdominal imaging;
* informed consent signed.

Exclusion Criteria

* Pregnant / lactating women；
* Contraindications of imaging examination。

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Weishen WANG

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

References

Explore related publications, articles, or registry entries linked to this study.

Fu N, Fu W, Chen H, Chai W, Qian X, Wang W, Jiang Y, Shen B. A deep-learning radiomics-based lymph node metastasis predictive model for pancreatic cancer: a diagnostic study. Int J Surg. 2023 Aug 1;109(8):2196-2203. doi: 10.1097/JS9.0000000000000469.

Reference Type DERIVED

PMID: 37216230 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Retro-001

Identifier Type: -

Identifier Source: org_study_id